Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 195

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 195
---
 discounting the contingent consideration receivable from Alfasigma for €4.0 million and a positive effect of discounting our long term deferred income of €0.2 million (€0.6 million discounting expenses of our long term deferred income in the same period last year). 
​
​
Results from our continuing Operations
Collaboration revenues

                               ​                                  ​    ​        ​        ​       ​        ​      ​    ​      ​  
--------------------------------------------------------------------------------------------------------------------------------
​                                                                 ​   Year ended December 31,                    ​   ​      ​   
​                                                                 2024                 2023                          % Change   
​                                                                 ​   ​                   (Euro, in thousands)   ​   ​      ​   
Recognition of non-refundable upfront payments and license fees   ​   €      230,182   ​       €       230,242   ​   ​      (0%)
Royalties                                                         ​   ​       10,604   ​       ​         9,482   ​   ​      12% 
Total collaboration revenues                                      ​   €      240,786   ​       €       239,724   ​   ​      0%  
​

​
142

We refer to note 2 “Summary of significant transactions” in our consolidated financial statements appended to this annual report for a general description of our collaboration with Gilead.
The following table summarizes details of collaboration revenues for the years ended December 31, 2024 and 2023 by collaboration and by category of revenue: upfront payments and license fees, and royalties.

                               ​                                  ​       ​       ​         ​         ​     ​        ​      ​     ​        ​   
-----------------------------------------------------------------------------------------------------------------------------------------------
​                                                                     Over time       Point in time   2024                      ​          2023
​                                                                 ​   ​           ​   ​               ​   (Euro, in         ​   (Euro, in      
​                                                                 ​   ​           ​   ​               ​   thousands)        ​   thousands)     
Recognition of non-refundable upfront payments and license fees   ​   ​           ​   ​               ​   €       230,182   ​   €       230,242
Gilead collaboration agreement for drug discovery platform        ​   Ö           ​   ​               ​   ​       230,182   ​   ​       230,242
​                                                                 ​   ​           ​   ​               ​   ​       ​         ​   ​             ​
Royalties                                                         ​